Algorae Pharmaceuticals Limited (ASX: 1AI) has taken another step in building its commercial presence within the Australian pharmaceutical market. The Company has entered into a distribution agreement with Dr. Reddy’s Laboratories Ltd (NSE: DRREDDY), marking a strategic shift from purely into tangible near-term revenue generation. The first shipment of Capecitabine 500mg tablets is scheduled to arrive in Australia in December 2025, positioning Algorae for an accelerated comme

Proteomics International Laboratories Ltd (ASX: PIQ) has released new clinical evidence demonstrating that its PromarkerD blood test (Figure 1) has meaningful predictive value for diabetic kidney disease (DKD) in Aboriginal Australians, one of the highest-risk populations globally. The findings are based on Australian clinical cohorts and reinforce the test’s relevance in addressing a major national health challenge.

Algorae Pharmaceuticals Ltd (ASX: 1AI), headquartered in Melbourne, has reported a significant technical milestone with the independent preclinical validation of its AI-driven drug-combination platform, AlgoraeOS v1 (AOS1). The validation, completed at the Victorian Centre for Functional Genomics (VCFG) at the Peter MacCallum Cancer Centre, provides the first external confirmation that AOS1 can identify synergistic drug pairs with real biological impact.

Proteomics International Laboratories Ltd (ASX: PIQ) has released new performance data from its majority-owned subsidiary, OxiDx Pty Ltd, in collaboration with The University of Western Australia. The findings were presented at the Australian Physiological Society (AuPS) Annual Scientific Meeting in Sydney, Australia, confirming that Thoroughbred racehorses competing without oxidative stress were significantly more likely to perform at higher levels.

Echo IQ Limited (ASX: EIQ), based in Sydney, has released new clinical insights presented at the AHA Scientific Sessions 2025 in New Orleans, highlighting the growing medical need and commercial opportunity for EchoSolv AS, the Company’s AI-powered decision-support tool for severe aortic stenosis (AS).

Race Oncology Limited (ASX: RAC) has announced the expansion of its clinical strategy with two new programs centred on Acute Myeloid Leukaemia (AML) and EGFR-mutated Non-Small Cell Lung Cancer (NSCLC). These programs build directly on the newly characterised mechanism of action of (E,E)-bisantrene and position RC220 for accelerated clinical validation across major oncology markets.

Proteomics International Laboratories Ltd (ASX: PIQ) has received $2.2 million in R&D tax incentive refunds for the 2024–25 financial year, reinforcing its financial position as the Company advances multiple diagnostic products towards commercialisation. Based in Perth, Western Australia, the Company continues to develop next-generation diagnostic tools built on its proprietary Promarker® technology platform, with applications across chronic disease detection, women’s health,

Emyria Limited (ASX: EMD) has taken another step toward building a national network of intensive, evidence-based mental health services in Australia. The Company has secured funding through an $8 million institutional placement and exercised a key option with Avive Health, paving the way for its first Empax Clinic in Victoria. At the same time, insurer-funded treatments have commenced at the Brisbane Empax Clinic, adding a second reimbursed site to the existing Empax Centre i

Echo IQ Limited (ASX: EIQ) is pushing its cardiology decision-support platform into the heart failure space, with its EchoSolv HF algorithm now validated through the Mayo Clinic Platform’s independent “Validate” program in the United States. The Company, based in Sydney with operations anchored out of Western Australia, has completed what it describes as the final clinical requirement ahead of a planned FDA 510(k) submission for EchoSolv HF – a heart failure decision-support

Algorae Pharmaceuticals Limited (ASX: 1AI) has launched AlgoraeOS Version 2, a major upgrade to its AI-driven platform for drug-combination discovery. Developed in partnership with UNSW Biomedical AI Laboratory, UNSW AI Institute, and CSIRO Data61, the new system represents a significant advancement in modelling complex therapeutic interactions.

Invion Limited (ASX: IVX) has signed a funded collaboration with Protect Animal Health Inc. (Taiwan, 7850.TT) to evaluate Photosoft™ in veterinary oncology across in-vitro, in-vivo, and companion-animal studies. Invion supplies compounds, Protect funds, and runs the work. Invion retains all Photosoft IP, with scope to move to a co-development/commercial agreement if results warrant.

Actinogen Medical (ASX: ACW) released two important updates dated 20 October 2025: (1) accelerated recruitment has enabled early closure of pTau screening for the Phase 2b/3 XanaMIA Alzheimer’s trial; and (2) an Advance Overseas Finding (AOF) approval confirms eligibility for a further RDTI rebate of ~$1.87m, taking the total FY25 RDTI to ~$7.36m if the ATO amendment is favourably assessed.

Proteomics International (ASX: PIQ) has expanded its research agreement with the University of Melbourne and the Royal Women’s Hospital (RWH), a leading centre for endometriosis research. The partnership has two clear streams: (1) additional clinical validation for Promarker®Endo—PIQ’s first-in-class blood test for diagnosing endometriosis—and (2) discovery work toward a tissue-specific, next-generation test using peritoneal fluid to improve disease localisation.

Medibank Private has expanded its multi-year funding agreement with Emyria Limited (ASX: EMD) to support screened and eligible customers accessing Empax programs for Treatment-Resistant Depression (TRD) and Post-Traumatic Stress Disorder (PTSD) at Avive Clinic Brisbane (Figure 1). Clinic fit-out and regulatory preparations are underway, with treatment commencement targeted for Q4 CY2025. This marks Emyria’s first insurer-backed program on Australia’s east coast and advances t

Algorae Pharmaceuticals Ltd (ASX: 1AI) has executed a binding term sheet with Cadila Pharmaceuticals Limited for a proposed license and supply agreement covering Australia and New Zealand. The partnership would see Algorae launch two generic medicines targeting cardiovascular and metabolic disorders, with next steps focused on finalising a definitive agreement and preparing for TGA registration.